A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms Her+XELOX
- 08 May 2019 Status changed from active, no longer recruiting to completed.
- 28 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
- 28 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.